Don’t see what you’re looking for? Use the search box on MDA’s Quest magazine.
Posted on Wednesday, May 1, 2013 - 09:23, By: Amy Madsen
How it works: Arimoclomol, developed by CytRx Corporation, is believed to work by increasing production of the so-called "chaperone" molecules heat-shock protein 70 and heat-shock protein 90. These molecules aid in cell repair by helping newly synthesized proteins fold correctly,...
Posted on Saturday, May 1, 2010 - 11:54, By: ALSN Staff
Cytokinetics seeks participants for CK-2017357 study
Cytokinetics, a South San Francisco biotechnology company, is seeking participants with ALS for a trial of its experimental compound CK-2017357.
After a two-year review, the FDA approves reopening a clinical trial of the experimental compound arimoclomol.
Posted on Tuesday, December 8, 2009 - 12:53, By: Margaret Wahl
A clinical trial of an experimental drug for ALS -- halted almost two years ago due to safety concerns –- has been given the green light to continue with a revised protocol, says CytRx Corp. of Los Angeles, the drug’s manufacturer.
The U.S. Food and Drug Administration placed a hold on the phase...
Posted on Tuesday, April 1, 2008 - 17:00, By: Margaret Wahl
FDA confirms rat study results are reason for arimoclomol trial hold
Posted on Friday, February 1, 2008 - 17:00, By: Margaret Wahl
CytRx to test arimoclomol at higher dose